Luye's SCLC therapy lurbinectedin under clinical trial review in China

China-based Luye Pharma Group (2186.HK) announced a clinical trial filing for LY01017 (lurbinectedin), an RNA polymerase II inhibitor licensed from Spain’s Pharma Mar SA. The filing has been accepted for review by China's Center for Drug Evaluation (CDE).

RNA polymerase II is an essential enzyme that facilitates the transcription process, and can be over-activated in tumors with transcriptional addiction. Lurbinectedin gained approval from the US FDA in June this year, and is marketed under the trade name Zepzelca for use in relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy treatment. The drug also hit Australia and Singapore via the Special Access Scheme, and has obtained orphan drug designations (ODDs) for SCLC in the US, European Union (EU), Switzerland, and Australia.

Luye struck a licensing deal with Pharma Mar in April 2019, taking exclusive development and commercialization rights to lurbinectedin in China. The Chinese biopharma also has the right to request a full technology transfer in relation to the molecule during the agreement period.


Related news
China-based Luye Pharma Group Ltd (HK.02186) announced that it has entered into a licensing agreement with Spain-headquartered Pharma Mar, S.A. (MCE: PHM) focused on the latter’s lurbinectedin (Zepsyre), an innovative cancer therapy currently at the Phase III clinical trial stage.
  • 1556431857507
  • China
  • Drug
Spain-based PharmaMar announced an agreement to license Austria-based Pint Pharma rights to develop and commercialize PharmaMar's multiple myeloma drug Aplidin (plitidepsin) in Latin America.
  • 1528747205438
  • Brazil,Mexico,Argentina,Colombia,Chile,Bolivia
  • Deals
Recent news
According to GBI analysis, Colombia’s National Food and Drug Surveillance Institute (INVIMA) recently approved Pfizer subsidiary Wyeth’s antihemorrhagic BeneFIX (recombinant coagulation factor IX), Pfizer’s human growth hormone analog Somavert (pegvisomant), and Mundipharma’s antineoplastic Difolta (pralatrexate).
Argentina’s Ministry of Health (MoH) this week launched two drug procurement processes.
Mexico’s Congress last week passed an Industrial Innovation Protection Law, which was announced last month.
Paraguay's Ministry of Health (MSPBS) this week launched its Drugs and Medical Supplies National Monitoring System, an online platform that keeps track of health products distribution in the public healthcare system as well as their cost.
Germany-based giant Merck KGaA has opened its M Lab Collaboration Center in Pudong, at the heart of the biomedical sciences and research community in Shanghai.
The cloud summit of World Artificial Intelligence Conference (WAIC) held in Shanghai this year saw China’s technology giant Tencent launch iDrug, its first AI-empowered drug research and development (R&D) platform, designed to galvanize novel drug development via technology. iDrug covers the whole process of pre-clinical development: protein structure screening, virtual screening, molecular design and optimization, and synthetic route planning.
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH) announced the go-ahead from the National Medical Products Administration (NMPA) to initiate a clinical study for its donafenib combined with Genor Biopharma Co., Ltd’s programmed death-1 (PD-1) inhibitor genolimzumab in advanced hepatocellular carcinoma (HCC), gastric cancer including gastroesophageal junction adenocarcinoma (GC/GEJ), renal cell carcinoma (RCC), colorectal cancer (CRC), and other advanced solid tumors. Donafenib (CM4307) is a small-molecule oral multi-kinase inhibitor with activity against serine-threonine kinase (Raf/MEK/ERK) signaling, vascular endothelial growth factor receptor (VEGFRs) and platelet-derived growth factor receptor (PDGFR), designed to directly and indirectly inhibit tumor cell proliferation and growth.
Analytics Snapshot

Analytics Snapshot